UK-based liquid biopsy firm Angle said today that it has inked a comarketing agreement with Qiagen for circulating tumor cell (CTC) technology.
{iframe}https://www.genomeweb.com/business-news/qiagen-angle-comarket-liquid-biopsy-technologies{/iframe}
Qiagen, Angle to Comarket Liquid Biopsy Technologies | GenomeWeb